Advertisement
CERS vs DXCM
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CERS is a Hold and DXCM is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CERS’s FA Score shows that 0 FA rating(s) are green whileDXCM’s FA Score has 1 green FA rating(s).
- CERS’s FA Score: 0 green, 5 red.
- DXCM’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CERS’s TA Score shows that 3 TA indicator(s) are bullish while DXCM’s TA Score has 2 bullish TA indicator(s).
- CERS’s TA Score: 3 bullish, 4 bearish.
- DXCM’s TA Score: 2 bullish, 4 bearish.
Price Growth
CERS (@Medical/Nursing Services) experienced а -2.33% price change this week, while DXCM (@Medical/Nursing Services) price change was -2.36% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +2.43%. For the same industry, the average monthly price growth was +6.56%, and the average quarterly price growth was +6.88%.
Reported Earning Dates
CERS is expected to report earnings on Oct 30, 2025.
DXCM is expected to report earnings on Oct 23, 2025.
Industries' Descriptions
@Medical/Nursing Services (+2.43% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| CERS | DXCM | CERS / DXCM | |
| Capitalization | 242M | 29.6B | 1% |
| EBITDA | -8.62M | 1.04B | -1% |
| Gain YTD | -18.182 | -1.569 | 1,159% |
| P/E Ratio | N/A | 53.91 | - |
| Revenue | 193M | 4.3B | 4% |
| Total Cash | 78M | 2.93B | 3% |
| Total Debt | 98.9M | 2.58B | 4% |
CERS | DXCM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 73 | 14 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 34 Fair valued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 41 | |
PRICE GROWTH RATING 1..100 | 84 | 61 | |
P/E GROWTH RATING 1..100 | 100 | 26 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CERS's Valuation (34) in the Medical Specialties industry is somewhat better than the same rating for DXCM (79). This means that CERS’s stock grew somewhat faster than DXCM’s over the last 12 months.
CERS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as DXCM (100). This means that CERS’s stock grew similarly to DXCM’s over the last 12 months.
DXCM's SMR Rating (41) in the Medical Specialties industry is somewhat better than the same rating for CERS (97). This means that DXCM’s stock grew somewhat faster than CERS’s over the last 12 months.
DXCM's Price Growth Rating (61) in the Medical Specialties industry is in the same range as CERS (84). This means that DXCM’s stock grew similarly to CERS’s over the last 12 months.
DXCM's P/E Growth Rating (26) in the Medical Specialties industry is significantly better than the same rating for CERS (100). This means that DXCM’s stock grew significantly faster than CERS’s over the last 12 months.
| CERS | DXCM | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 73% | 1 day ago 66% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 76% |
| MACD ODDS (%) | 1 day ago 87% | 1 day ago 70% |
| TrendWeek ODDS (%) | 1 day ago 85% | 1 day ago 68% |
| TrendMonth ODDS (%) | 1 day ago 82% | 1 day ago 70% |
| Advances ODDS (%) | 14 days ago 75% | 14 days ago 71% |
| Declines ODDS (%) | 3 days ago 85% | 10 days ago 71% |
| BollingerBands ODDS (%) | 1 day ago 80% | N/A |
| Aroon ODDS (%) | 1 day ago 86% | 1 day ago 65% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DFEN | 62.18 | 0.78 | +1.27% |
| Direxion Dly Aerospace&Def Bl 3X ShsETF | |||
| EOCT | 30.53 | 0.10 | +0.33% |
| Innovator Emerg Mkts Pwr Bffr ETF™-Oct | |||
| AVIE | 62.48 | 0.21 | +0.33% |
| Avantis Inflation Focused Equity ETF | |||
| XHB | 115.02 | -0.44 | -0.38% |
| SPDR® S&P Homebuilders ETF | |||
| IYRI | 50.64 | -0.24 | -0.47% |
| NEOS Real Estate High Income ETF | |||